Abstract: A process for stereoselectively forming N-substituted dihydro-2,3 benzodiazepines which are useful as AMPA receptor antagonists. The process includes an opening reduction step which sets the stereochemistry of the intermediates and the final compounds to the desired enantiomer. The reduction step may be carried out by an enzymatic reduction.
Type:
Grant
Filed:
July 2, 1999
Date of Patent:
December 12, 2000
Assignee:
Eli Lilly and Company
Inventors:
David L. Varie, Jeffrey T. Vicenzi, Milton J. Zmijewski